Skip to Content

Posts tagged with "Cancer"

  • Cancer

    More Than Was Asked For

    Via AndyBiotech on Twitter, here’s an interesting report from the New England Journal of Medicine. It describes a patient diagnosed with follicular lymphoma who also was positive for hepatitis C. They went through a course of Gilead’s sofosbuvir with ribavirin, and that (as it usually does) cleared the Hep C infection. What’s inte… Read More
  • Alzheimer's Disease

    The Limits of Big Data

    I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they have podiatrist appointments or something. But that’s the only way to approach this article at Wired. After all, the title is “The Cure For Cancer is Data – Mountains of… Read More
  • Cancer

    Keytruda vs. Opdivo: No Contest

    You don’t always get to see a head-to-head showdown like this one: Merck’s Keytruda (pembrolizumab) and Bristol Myers-Squibb’s Opdivo (nivolumab) were both the subject of presentations at the European Society of Medical Oncology conference, reporting on non-small cell lung cancer trials, and there doesn’t seem to be any doub… Read More
  • Cancer

    Better, Faster, More Comprehensive Manure Distribution

    So today brings news that Microsoft is working on curing cancer in the next five or ten years. That, I’m sure, will come as a relief, especially to those people who’ve had the company’s software crash on them recently. For some reason, the UK press is especially susceptible to Amazing Cancer Cure stories (and to… Read More
  • Cancer

    Precision Oncology Isn’t Quite There Yet

    Here’s a gauntlet thrown down – let’s see how many people show up to the duel. Vinay Prasad has a piece in Nature titled “The Precision Oncology Illusion”, with the subhead saying “Precision oncology has not been shown to work, and perhaps it never will”. (Here’s Prasad earlier this year, with co-auth… Read More
  • Cancer

    Pancreatic Cancer Progress? Maybe

    There’s been a vast amount of work (and excitement) in the immunotherapy approaches to cancer in the last few years. Here’s a report on one that I’d missed: IMM-101, which is not directed to PD-1 or PD-1L1, not an engineered T-cell, or any of the other things that have been in the news. It’s a… Read More
  • Cancer

    Novartis and CAR-T: What’s Going On?

    The upheaval in the Novartis CAR-T program happened while I was off at a conference last week and unable to give it a full treatment. So now that it’s happened, let’s think about it a bit. The folks at Endpoints have been a good source of info on this story, and it appears that Novartis… Read More
  • Analytical Chemistry

    Not So Fast on the PD-L1 Comparisons

    We may have to rethink what we think about the recent trial in which Bristol-Myers Squibb’s Opdivo was ineffective in non-small cell lung cancer. The arguing has been about the status of the patients, specifically how much PD-L1 protein they were expressing. But writing in BioCentury, Stephen Hansen points out that comparing the various trial… Read More
  • Business and Markets

    Pfizer Buys Medivation

    I wonder how many people have been holding Medivation shares through the years, all the way through? If you have, you must have forgotten that you owned the stuff, because the temptation to unload them, on good news and bad, has been very strong at times. Back in 2010, the company was developing an oddball… Read More
  • Cancer

    3-Bromopyruvate: What a Mess

    There have been several reports of the use of 3-bromopyruvate as an anticancer therapy, despite (as far as I can see) a lack of any controlled human data. People occasionally bring it up in the comments here, but I’ve never written on it myself. The literature has a number of papers on its effects in… Read More